BR0214137A - Anticorpos para o cd40, composição farmacêutica compreendendo os mesmos, uso dos mesmos na fabricação de um medicamento, linhagem, de célula isolada, molécula de ácido nucléico isolada, vetor compreendendo a mesma, célula hospedeira e método de fabricação dos referidos anticorpos - Google Patents
Anticorpos para o cd40, composição farmacêutica compreendendo os mesmos, uso dos mesmos na fabricação de um medicamento, linhagem, de célula isolada, molécula de ácido nucléico isolada, vetor compreendendo a mesma, célula hospedeira e método de fabricação dos referidos anticorposInfo
- Publication number
- BR0214137A BR0214137A BR0214137-0A BR0214137A BR0214137A BR 0214137 A BR0214137 A BR 0214137A BR 0214137 A BR0214137 A BR 0214137A BR 0214137 A BR0214137 A BR 0214137A
- Authority
- BR
- Brazil
- Prior art keywords
- antibodies
- nucleic acid
- relates
- isolated
- same
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/062—Photodynamic therapy, i.e. excitation of an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34898001P | 2001-11-09 | 2001-11-09 | |
US60/348,980 | 2001-11-09 | ||
PCT/US2002/036107 WO2003040170A2 (en) | 2001-11-09 | 2002-11-08 | Antibodies to cd40 |
Publications (3)
Publication Number | Publication Date |
---|---|
BR0214137A true BR0214137A (pt) | 2004-09-14 |
BRPI0214137B1 BRPI0214137B1 (pt) | 2019-03-19 |
BRPI0214137B8 BRPI0214137B8 (pt) | 2021-05-25 |
Family
ID=23370387
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0214137A BRPI0214137B8 (pt) | 2001-11-09 | 2002-11-08 | anticorpo monoclonal humano ou porção de ligação a antígeno do mesmo que se liga especificamente ao cd40 humano e o ativa, linhagem celular de hibridoma isolado, composição farmacêutica compreendendo os mesmos, uso dos mesmos na fabricação de um medicamento e método de fabricação dos referidos anticorpos ou porção de ligação a antígeno do mesmo |
Country Status (47)
Families Citing this family (243)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7244827B2 (en) * | 2000-04-12 | 2007-07-17 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 24P4C12 useful in treatment and detection of cancer |
US6943235B1 (en) * | 1999-04-12 | 2005-09-13 | Agensys, Inc. | Transmembrane protein expressed in prostate cancer |
US20050255106A1 (en) * | 1999-05-22 | 2005-11-17 | Linda Diehl | Induction of anti-tumor ctl immunity through in vivo triggering of 4-1bb and/or cd40 |
US20030059427A1 (en) * | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
CA2422204A1 (en) | 2000-09-07 | 2002-03-14 | John R. Schreiber | Human antibodies against pseudomonas aeruginosa lps derived from transgenic mice |
EP2009027B1 (en) | 2001-04-27 | 2014-05-21 | Kyowa Hakko Kirin Co., Ltd. | Anti-CD40 monoclonal antibody |
US7658924B2 (en) * | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
AU2002357759A1 (en) | 2001-11-21 | 2003-06-10 | Mark W. Appelby | Manipulation of cytokine levels using cd83 gene products |
US20040185040A1 (en) | 2001-11-21 | 2004-09-23 | Celltech R & D Limited | Modulating immune responses |
EP1531850B1 (en) * | 2002-06-07 | 2012-02-22 | ZymoGenetics, Inc. | Use of IL-21 and monoclonal antibody for treating solid cancers |
US7052694B2 (en) * | 2002-07-16 | 2006-05-30 | Mayo Foundation For Medical Education And Research | Dendritic cell potentiation |
HN2004000285A (es) * | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
CA2542638A1 (en) * | 2003-10-16 | 2005-04-28 | Imclone Systems Incorporated | Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof |
ATE447412T1 (de) * | 2003-11-04 | 2009-11-15 | Novartis Vaccines & Diagnostic | Antagonist-anti-cd40-monoklonale antikörper und anwendungsverfahren |
US8277810B2 (en) | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
EP1706425A2 (en) | 2003-12-05 | 2006-10-04 | John R. Schreiber | Human anti-pseudomonas-aeruginosa antibodies derived from transgenic xenomouse® |
US20050136055A1 (en) * | 2003-12-22 | 2005-06-23 | Pfizer Inc | CD40 antibody formulation and methods |
TW200540186A (en) * | 2003-12-25 | 2005-12-16 | Kirin Brewery | Mutants of anti-CD40 antibody |
SV2006001990A (es) | 2004-01-09 | 2006-01-30 | Pfizer | Anticuerpos contra madcam |
CN1980957A (zh) | 2004-03-23 | 2007-06-13 | 比奥根艾迪克Ma公司 | 受体偶联剂及其治疗用途 |
US20060099203A1 (en) | 2004-11-05 | 2006-05-11 | Pease Larry R | B7-DC binding antibody |
EP2481750A1 (en) * | 2004-06-30 | 2012-08-01 | Mayo Foundation for Medical Education and Research | B7-DC binding antibody |
PL2287195T3 (pl) | 2004-07-01 | 2019-10-31 | Novo Nordisk As | Przeciwciała pan-kir2dl receptora nk i ich zastosowanie w diagnostyce i terapii |
WO2006017574A1 (en) * | 2004-08-03 | 2006-02-16 | Mayo Foundation For Medical Education And Research | Improving treatments |
US7563443B2 (en) * | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
CN104829720B (zh) | 2005-01-06 | 2019-01-01 | 诺和诺德公司 | Kir结合剂和使用其的方法 |
US8716451B2 (en) | 2005-01-12 | 2014-05-06 | Kyowa Hakko Kirin Co., Ltd | Stabilized human IgG2 and IgG3 antibodies |
SG10201912554TA (en) * | 2005-03-23 | 2020-02-27 | Genmab As | Antibodies against cd38 for treatment of multiple myeloma |
BRPI0608096A2 (pt) | 2005-04-26 | 2009-11-10 | Pfizer | anticorpos p-caderina |
EP1894012A2 (en) * | 2005-05-18 | 2008-03-05 | Novartis AG | Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling |
DK1889065T3 (da) * | 2005-05-18 | 2013-09-02 | Xoma Technology Ltd | Metoder til diagnostisering og behandling af sygdomme med en autoimmun- og/eller inflammationskomponent |
GB0512225D0 (en) * | 2005-06-16 | 2005-07-27 | Univ Sheffield | Immunoglobulin molecules |
AU2006269940C1 (en) | 2005-07-18 | 2013-11-07 | Seagen Inc. | Beta-glucuronide-linker drug conjugates |
UA94060C2 (ru) | 2005-09-07 | 2011-04-11 | Эмджен Фримонт Инк. | Моноклональное антитело, которое специфически связывает alk-1 |
WO2007103048A2 (en) * | 2006-03-01 | 2007-09-13 | Regents Of The University Of Colorado | Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity |
MX2008013993A (es) * | 2006-05-03 | 2009-05-11 | Univ Colorado | Combinación adyuvante sinergistica de anticuerpo agonista de cd40/interferona tipo 1, conjugados que la contienen y uso de los mismos como un terapeutico para aumentar la inmunidad celular. |
EP1854810A1 (en) * | 2006-05-09 | 2007-11-14 | PanGenetics B.V. | Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody |
EA200802058A1 (ru) | 2006-05-09 | 2009-06-30 | Пфайзер Продактс Инк. | Производные циклоалкиламинокислот и их фармацевтические композиции |
CA2652148C (en) * | 2006-05-12 | 2016-10-04 | Fondazione Centro San Raffaele Del Monte Tabor | Tolerogenic dendritic cells, method for their production and uses thereof |
US20090074711A1 (en) * | 2006-09-07 | 2009-03-19 | University Of Southhampton | Human therapies using chimeric agonistic anti-human cd40 antibody |
EP2103628A4 (en) * | 2006-12-14 | 2012-02-22 | Forerunner Pharma Res Co Ltd | MONOCLONAL ANTIBODY ANTI-CLAUDIN 3, AND TREATMENT AND DIAGNOSIS OF CANCER USING SUCH ANTIBODY |
US20100111966A1 (en) * | 2007-02-23 | 2010-05-06 | Schering Corporation | Engineered anti-il-23p19 antibodies |
CA2678749C (en) | 2007-02-23 | 2018-03-13 | Schering Corporation | Engineered anti-il-23p19 antibodies |
LT2176298T (lt) | 2007-05-30 | 2018-04-10 | Xencor, Inc. | Būdai ir kompozicijos, skirti cd32b ekspresuojančių ląstelių slopinimui |
EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
US8039597B2 (en) * | 2007-09-07 | 2011-10-18 | Agensys, Inc. | Antibodies and related molecules that bind to 24P4C12 proteins |
JP5730576B2 (ja) | 2007-11-07 | 2015-06-10 | ジェネンテック, インコーポレイテッド | 抗cd40抗体による治療に対するb細胞リンパ腫の応答性を評価するための方法及び組成物 |
CN101918447B (zh) | 2007-12-14 | 2014-06-11 | 布里斯托尔-米尔斯·斯奎布公司 | 人ox40受体的结合分子 |
JO2913B1 (en) * | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
AU2010222929B2 (en) * | 2008-07-16 | 2013-07-25 | Baylor Research Institute | Antigen presenting cell targeted anti-viral vaccines |
US8518952B2 (en) | 2008-08-06 | 2013-08-27 | Pfizer Inc. | 6 substituted 2-heterocyclylamino pyrazine compounds as CHK-1 inhibitors |
EP2323690A1 (en) * | 2008-08-29 | 2011-05-25 | Academisch Ziekenhuis Leiden h.o.d.n. LUMC | Delivery of a cd40 agonist to a tumor draining lymph node of a subject |
EP2198878A1 (en) | 2008-12-18 | 2010-06-23 | University Of Miami | Polypeptide bombesin antagonists |
JO3382B1 (ar) * | 2008-12-23 | 2019-03-13 | Amgen Inc | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
AU2016244220B2 (en) * | 2008-12-23 | 2018-05-17 | Amgen Inc. | Human CGRP receptor binding proteins |
CA2754531A1 (en) * | 2009-03-06 | 2010-09-30 | Seattle Genetics, Inc. | Antibody drug conjugates (adc) that bind to 24p4c12 proteins |
US9562104B2 (en) | 2009-03-10 | 2017-02-07 | Baylor Research Institute | Anti-CD40 antibodies |
DK2406289T3 (en) | 2009-03-10 | 2017-05-01 | Baylor Res Inst | ANTIGEN PRESENTING CELL TARGETED ANTIVIRUS VACCINES |
CA2758523C (en) | 2009-04-18 | 2019-03-12 | Genentech, Inc. | Methods for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies |
EP2423228B1 (en) | 2009-04-20 | 2015-12-16 | Kyowa Hakko Kirin Co., Ltd. | Antibody containing igg2 having amino acid mutation introduced therein |
TW201138843A (en) | 2009-12-18 | 2011-11-16 | Colgate Palmolive Co | Biguanide preservation of precipitated calcium carbonate |
WO2011083391A2 (en) | 2010-01-05 | 2011-07-14 | Pfizer Inc. | Biomarkers for anti-igf-ir cancer therapy |
HUE038788T2 (hu) | 2010-03-31 | 2018-11-28 | Boehringer Ingelheim Int | Anti-CD40 antitestek |
GB201006096D0 (en) * | 2010-04-13 | 2010-05-26 | Alligator Bioscience Ab | Novel compositions and uses thereof |
FR2959994B1 (fr) * | 2010-05-12 | 2012-08-24 | Lfb Biotechnologies | Nouveaux anticorps humanises 12g4 mutes et leurs fragments diriges contre le recepteur humain de l'hormone anti-mullerienne de type ii |
KR101527300B1 (ko) | 2010-09-09 | 2015-06-09 | 화이자 인코포레이티드 | 4-1bb 결합 분자 |
CA2805361A1 (en) * | 2010-09-29 | 2012-04-05 | Universite De Liege | Combination of an agonistic anti-cd40 monoclonal antibody or a cd40 ligand and inactivated or attenuated bacteria for use in the treatment and/or prevention of mastitis |
AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
EP3974453A3 (en) * | 2010-11-16 | 2022-08-03 | Amgen Inc. | Agents and methods for treating diseases that correlate with bcma expression |
CN103347898B (zh) * | 2011-01-10 | 2017-12-05 | Ct大西洋有限公司 | 包括与肿瘤相关抗原结合抗体的联合治疗 |
GB201103578D0 (en) | 2011-03-02 | 2011-04-13 | Sabrepharm Ltd | Dipyridinium derivatives |
PT2683406T (pt) * | 2011-03-11 | 2019-07-08 | Beth Israel Deaconess Medical Ct Inc | Anticorpos anti-cd40 e utilização dos mesmos |
EP2699598B1 (en) | 2011-04-19 | 2019-03-06 | Pfizer Inc | Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer |
KR20140059168A (ko) * | 2011-04-21 | 2014-05-15 | 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 | 시신경 척수염 치료용 조성물 및 치료 방법 |
AU2012245309C1 (en) | 2011-04-21 | 2016-07-21 | Bristol-Myers Squibb Company | Antibody polypeptides that antagonize CD40 |
EP3508500A1 (en) | 2011-04-29 | 2019-07-10 | Apexigen, Inc. | Anti-cd40 antibodies and methods of use |
CN103842383B (zh) | 2011-05-16 | 2017-11-03 | 健能隆医药技术(上海)有限公司 | 多特异性fab融合蛋白及其使用方法 |
GB201115280D0 (en) * | 2011-09-05 | 2011-10-19 | Alligator Bioscience Ab | Antibodies, uses and methods |
GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
MX353958B (es) * | 2011-09-22 | 2018-02-07 | Amgen Inc | Proteinas de union al antigeno cd27l. |
EP3559049A4 (en) | 2011-10-28 | 2019-12-04 | Teva Pharmaceuticals Australia Pty Ltd | POLYPEPTIDE CONSTRUCTS AND APPLICATIONS THEREOF |
WO2013091661A2 (en) * | 2011-12-23 | 2013-06-27 | Aarhus Universitet | Proteolytic resistant protein affinity tag |
DK3453723T3 (da) | 2012-01-31 | 2021-09-13 | Regeneron Pharma | Anti-ASIC1-antistoffer og anvendelser deraf |
AR090263A1 (es) * | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
US20150064203A1 (en) * | 2012-03-08 | 2015-03-05 | Japan Science And Technology Agency | Anticancer agent |
DK2844282T3 (da) | 2012-05-04 | 2019-07-15 | Pfizer | Prostata-associerede antigener og vaccine-baserede immunterapiregimener |
US20140004131A1 (en) | 2012-05-04 | 2014-01-02 | Novartis Ag | Antibody formulation |
ES2873877T3 (es) | 2012-06-18 | 2021-11-04 | Ospedale San Raffaele Srl | Composiciones y métodos para disminuir una respuesta inmune |
CN104918957B (zh) * | 2012-10-30 | 2018-11-16 | 埃派斯进有限公司 | 抗-cd40抗体及其使用方法 |
UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
CA2899960C (en) | 2013-02-01 | 2022-05-03 | Transbio Ltd | Anti-cd83 antibodies and use thereof |
US9708375B2 (en) | 2013-03-15 | 2017-07-18 | Amgen Inc. | Inhibitory polypeptides specific to WNT inhibitors |
RS57840B1 (sr) | 2013-03-18 | 2018-12-31 | Biocerox Prod Bv | Humanizovana anti-cd 134 (ox40) antitela i njihove upotrebe |
EP2992013B1 (en) | 2013-04-29 | 2019-12-04 | Teva Pharmaceuticals Australia Pty Ltd | Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b |
US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
JP6450750B2 (ja) | 2013-06-17 | 2019-01-09 | コーニンクレッカ フィリップス エヌ ヴェKoninklijke Philips N.V. | 磁気共鳴画像化被験者支持器 |
GB201311487D0 (en) * | 2013-06-27 | 2013-08-14 | Alligator Bioscience Ab | Bispecific molecules |
JP6649254B2 (ja) | 2013-08-08 | 2020-02-19 | サイチューン ファーマ | IL−15及びIL−15Rαスシドメインに基づくモジュロカイン |
EP3712166A1 (en) | 2013-09-05 | 2020-09-23 | Amgen Inc. | Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles |
AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
CA2927968C (en) | 2013-10-25 | 2023-02-21 | Psioxus Therapeutics Limited | Oncolytic adenoviruses armed with heterologous genes |
GB201322583D0 (en) * | 2013-12-19 | 2014-02-05 | Alligator Bioscience Ab | Antibodies |
MX2016008099A (es) * | 2013-12-20 | 2016-10-13 | Hoffmann La Roche | Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40. |
AU2015204503B2 (en) | 2014-01-13 | 2020-07-09 | Baylor Research Institute | Novel vaccines against HPV and HPV-related diseases |
EP3113796A1 (en) | 2014-03-07 | 2017-01-11 | Bristol-Myers Squibb Company | Method of using antibody polypeptides that antagonize cd40 to treat ibd |
WO2015153514A1 (en) | 2014-03-31 | 2015-10-08 | Genentech, Inc. | Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists |
US10144782B2 (en) * | 2014-04-30 | 2018-12-04 | Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft | Humanized antibodies against CD269 (BCMA) |
UA119352C2 (uk) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
WO2015175861A1 (en) | 2014-05-16 | 2015-11-19 | Amgen Inc. | Assay for detecting th1 and th2 cell populations |
GB201413665D0 (en) | 2014-07-03 | 2014-09-17 | Transimmune Ag And Yale University | Method for obtaining globally activated monocytes |
MX2017001864A (es) | 2014-08-12 | 2017-08-02 | Alligator Bioscience Ab | Tratamientos conjuntos con anticuerpos anti cd40. |
RU2017108173A (ru) * | 2014-08-14 | 2018-09-17 | Ф.Хоффманн-Ля Рош Аг | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 |
EP3070102A1 (en) | 2015-03-18 | 2016-09-21 | F. Hoffmann-La Roche AG | Combination therapy of antibodies human cd40 activating antibodies and anti human pld-1 antibodies |
CA2960756C (en) | 2014-09-15 | 2023-08-01 | Amgen Inc. | Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof |
US10870704B2 (en) | 2014-10-23 | 2020-12-22 | Kira Biotech Pty Limited | CD83 binding proteins and uses thereof |
US9107906B1 (en) | 2014-10-28 | 2015-08-18 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
SG11201702598XA (en) | 2014-10-29 | 2017-05-30 | Seattle Genetics Inc | Dosage and administration of non-fucosylated anti-cd40 antibodies |
AU2015337858B2 (en) | 2014-10-29 | 2020-09-24 | Teva Pharmaceuticals Australia Pty Ltd. | Interferon alpha2b variants |
TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗pd-1抗體類和使用彼等之方法 |
BR112017020952A2 (pt) | 2015-04-13 | 2018-07-10 | Five Prime Therapeutics Inc | método de tratamento de câncer, composição e uso da composição |
JOP20200116A1 (ar) | 2015-04-24 | 2017-06-16 | Amgen Inc | طرق لعلاج أو الوقاية من الصداع النصفي |
PT3288573T (pt) | 2015-04-30 | 2020-03-25 | Psioxus Therapeutics Ltd | Adenovírus oncolítico que codifica uma proteína b7 |
DK3313879T3 (da) | 2015-06-24 | 2022-03-14 | Hoffmann La Roche | Anti-transferrinreceptor-antistoffer med tilpasset affinitet |
AU2016285920A1 (en) * | 2015-06-29 | 2018-02-01 | Bristol-Myers Squibb Company | Antibodies to CD40 with enhanced agonist activity |
CN115838427A (zh) * | 2015-06-29 | 2023-03-24 | 百时美施贵宝公司 | 针对cd40的抗体 |
EP3322431A2 (en) | 2015-07-16 | 2018-05-23 | Biokine Therapeutics Ltd. | Compositions and methods for treating cancer |
CN116063481A (zh) * | 2015-09-04 | 2023-05-05 | 普里玛托普医疗股份有限公司 | 人源化抗-cd40抗体及其用途 |
CN109069622A (zh) | 2015-09-30 | 2018-12-21 | 詹森生物科技公司 | 特异性结合人cd40的拮抗性抗体和使用方法 |
CN114014936A (zh) | 2015-10-02 | 2022-02-08 | 豪夫迈·罗氏有限公司 | 双特异性抗人cd20/人转铁蛋白受体抗体及使用方法 |
AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
GB2543550A (en) | 2015-10-21 | 2017-04-26 | Hox Therapeutics Ltd | Peptides |
BR112018008904A2 (pt) | 2015-11-03 | 2018-11-27 | Janssen Biotech Inc | anticorpos que se ligam especificamente a tim-3 e seus usos |
EP3964522A1 (en) * | 2015-11-16 | 2022-03-09 | Ubiprotein, Corp. | A method for extending half-life of a protein |
DE212016000029U1 (de) * | 2015-12-07 | 2017-07-30 | Opi Vi - Ip Holdco Llc | Zusammensetzungen von Antikörperkonstrukt-Agonist-Konjugaten |
AU2016372576A1 (en) | 2015-12-17 | 2018-06-21 | Psioxus Therapeutics Limited | Virus encoding an anti-TCR-complex antibody or fragment |
SG11201807677YA (en) * | 2016-03-04 | 2018-10-30 | Univ Rockefeller | Antibodies to cd40 with enhanced agonist activity |
WO2017156349A1 (en) | 2016-03-10 | 2017-09-14 | Cold Genesys, Inc. | Methods of treating solid or lymphatic tumors by combination therapy |
EP3430058A4 (en) | 2016-03-15 | 2019-10-23 | Generon (Shanghai) Corporation Ltd. | MULTISPECIFIC FAB FUSION PROTEINS AND USES THEREOF |
WO2017165681A1 (en) | 2016-03-24 | 2017-09-28 | Gensun Biopharma Inc. | Trispecific inhibitors for cancer treatment |
AU2017237186A1 (en) | 2016-03-25 | 2018-11-01 | Seagen Inc. | Process for the preparation of PEGylated drug-linkers and intermediates thereof |
EP3464367B1 (en) | 2016-05-27 | 2020-09-09 | AbbVie Biotherapeutics Inc. | Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen |
JP2019523221A (ja) | 2016-05-27 | 2019-08-22 | アッヴィ・バイオセラピューティクス・インコーポレイテッド | 抗cd40抗体とその使用 |
EP3468997B1 (en) | 2016-06-08 | 2023-09-13 | Xencor, Inc. | Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b |
JP2019528082A (ja) | 2016-06-08 | 2019-10-10 | シャンハイ ジャオ トン ユニバーシティ スクール オブ メディシン | アゴニスト抗体の活性を増強する抗体重鎖定常領域配列 |
TWI784957B (zh) | 2016-06-20 | 2022-12-01 | 英商克馬伯有限公司 | 免疫細胞介素 |
CN109641959B (zh) | 2016-07-14 | 2023-08-22 | 健玛保 | 针对cd40和cd137的多特异性抗体 |
WO2018014067A1 (en) | 2016-07-19 | 2018-01-25 | Teva Pharmaceuticals Australia Pty Ltd | Anti-cd47 combination therapy |
CN109843916B (zh) | 2016-08-12 | 2023-10-31 | 詹森生物科技公司 | 具有增强的激动活性的Fc工程化抗TNFR超家族成员抗体及其使用方法 |
EP3497120A1 (en) | 2016-08-12 | 2019-06-19 | Janssen Biotech, Inc. | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions |
WO2018036852A1 (en) | 2016-08-25 | 2018-03-01 | F. Hoffmann-La Roche Ag | Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent |
GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
US11905331B2 (en) | 2016-11-11 | 2024-02-20 | Kumho Ht, Inc. | Antibody binding specifically to CD40 and use thereof |
US20200347143A1 (en) | 2016-12-19 | 2020-11-05 | Glenmark Pharmaceuticals S.A. | Novel tnfr agonists and uses thereof |
JP7304287B2 (ja) | 2016-12-22 | 2023-07-06 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 抗pd-l1/pd1治療の不成功後の、抗pd-l1抗体との組み合わせでの抗csf-1r抗体を用いた腫瘍の治療 |
EP3565839A4 (en) | 2017-01-05 | 2021-04-21 | Gensun Biopharma Inc. | CHECKPOINT REGULATOR ANTAGONISTS |
WO2018144955A1 (en) * | 2017-02-02 | 2018-08-09 | Silverback Therapeutics, Inc. | Construct-peptide compositions and methods of use thereof |
WO2018146317A1 (en) | 2017-02-10 | 2018-08-16 | Genmab B.V. | Polypeptide variants and uses thereof |
AU2018235928B2 (en) | 2017-03-14 | 2023-09-21 | Amgen Inc. | Control of total afucosylated glycoforms of antibodies produced in cell culture |
US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
US11730822B2 (en) | 2017-03-24 | 2023-08-22 | Seagen Inc. | Process for the preparation of glucuronide drug-linkers and intermediates thereof |
CN110382541A (zh) * | 2017-03-29 | 2019-10-25 | 葛莱高托普有限公司 | 人源化抗cd40抗体 |
WO2018181059A1 (ja) | 2017-03-30 | 2018-10-04 | 日油株式会社 | ヘテロ二官能性単分散ポリエチレングリコール及びそれを用いた複合体 |
EP3604384B1 (en) | 2017-03-30 | 2021-09-08 | NOF Corporation | Hydrophilic polymer derivative having self-immolative acetal linker and composite using same |
BR112019017753A2 (pt) * | 2017-04-04 | 2020-04-07 | Hoffmann La Roche | molécula biespecífica, polinucleotídeo, vetor, célula, métodos para a produção de uma molécula e para o tratamento de um indivíduo, composição e uso da molécula biespecífica |
AU2018250875A1 (en) | 2017-04-13 | 2019-10-03 | F. Hoffmann-La Roche Ag | An interleukin-2 immunoconjugate, a CD40 agonist, and optionally a PD-1 axis binding antagonist for use in methods of treating cancer |
HUE063274T2 (hu) | 2017-06-01 | 2024-01-28 | Akamis Bio Ltd | Onkolitikus vírus és eljárás |
MX2019014375A (es) | 2017-06-01 | 2020-01-23 | Jiangsu Hengrui Medicine Co | Anticuerpo anti-cd40, fragmento de union a antigeno del mismo, y uso medico del mismo. |
CN110506058A (zh) * | 2017-06-02 | 2019-11-26 | 豪夫迈·罗氏有限公司 | 免疫激动剂的施用路径 |
EP3418302A1 (en) | 2017-06-19 | 2018-12-26 | F. Hoffmann-La Roche AG | Administration routes for immune agonists |
SG11202000298VA (en) | 2017-07-14 | 2020-02-27 | Pfizer | Antibodies to madcam |
CN111511762A (zh) | 2017-08-21 | 2020-08-07 | 天演药业公司 | 抗cd137分子及其用途 |
WO2019057792A1 (en) * | 2017-09-19 | 2019-03-28 | Mab Discovery Gmbh | CD40 ANTIBODY AGONISTS |
US10610585B2 (en) | 2017-09-26 | 2020-04-07 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for treating and preventing HIV |
AU2018363922A1 (en) | 2017-11-08 | 2020-05-28 | Kyowa Kirin Co., Ltd. | Bispecific antibody which binds to CD40 and EpCAM |
EP3732198A1 (en) | 2017-12-27 | 2020-11-04 | Bristol-Myers Squibb Company | Anti-cd40 antibodies and uses thereof |
CN109971723B (zh) * | 2017-12-28 | 2023-07-07 | 上海细胞治疗研究院 | 包含CD40抗体与muc1特异性嵌合抗原受体基因的T细胞及其用途 |
CN109971717B (zh) * | 2017-12-28 | 2023-06-20 | 上海细胞治疗研究院 | 共表达cd40抗体与间皮素特异性嵌合抗原受体的t细胞及其用途 |
WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
WO2019148444A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
CA3093645A1 (en) | 2018-03-13 | 2019-09-19 | Nof Corporation | Heterobifunctional compound having monodispersed polyethylene glycol in main chain and side chain |
MA52186A (fr) | 2018-03-26 | 2021-02-17 | Amgen Inc | Glycoformes afucosylées totales d'anticorps produits en culture cellulaire |
KR20200139720A (ko) | 2018-04-02 | 2020-12-14 | 암젠 인크 | 에레누맙 조성물 및 이의 용도 |
US20210179727A1 (en) * | 2018-04-20 | 2021-06-17 | Lyvgen Biopharma Co., Ltd. | Anti-cd40 antibodies and uses thereof |
US20200017596A1 (en) * | 2018-05-10 | 2020-01-16 | Abvision, Inc. | Monoclonal antibodies activating cd40 and uses thereof |
WO2019232533A1 (en) * | 2018-06-01 | 2019-12-05 | Massachusetts Institute Of Technology | Combination treatments of hsp90 inhibitors for enhancing tumor immunogenicity and methods of use thereof |
EP3806848A2 (en) | 2018-06-15 | 2021-04-21 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
WO2020006511A1 (en) | 2018-06-29 | 2020-01-02 | Gensun Biopharma, Inc. | Trispecific antagonists |
AU2019323790A1 (en) | 2018-08-20 | 2021-03-11 | Pfizer Inc. | Anti-GDF15 antibodies, compositions and methods of use |
WO2020070288A1 (en) | 2018-10-05 | 2020-04-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and systems for controlling the agonistic properties of antibody variable domains by light |
KR20210097750A (ko) | 2018-11-30 | 2021-08-09 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | Cd40 항체 약학 조성물 및 이의 용도 |
TW202039558A (zh) | 2018-11-30 | 2020-11-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗cd40抗體、其抗原結合片段及其醫藥用途 |
CN113677365A (zh) * | 2019-01-22 | 2021-11-19 | 瑞伟生物科技公司(美国) | 新型抗cd40抗体 |
US10570210B1 (en) | 2019-03-04 | 2020-02-25 | Beijing Mabworks Biotech Co.Ltd | Antibodies binding CD40 and uses thereof |
CN113811547A (zh) | 2019-03-27 | 2021-12-17 | 国家医疗保健研究所 | 具有cd40激活特性的重组蛋白 |
AU2020256828A1 (en) | 2019-04-10 | 2021-11-18 | Nankai University | Anti-CD40 antibody and use thereof |
MA55805A (fr) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | Métodes de modulation de l'activité immunitaire |
JPWO2020230899A1 (pt) | 2019-05-15 | 2020-11-19 | ||
JPWO2020230901A1 (pt) | 2019-05-15 | 2020-11-19 | ||
US10851157B2 (en) | 2019-07-01 | 2020-12-01 | Gensun Biopharma, Inc. | Antagonists targeting the TGF-β pathway |
WO2021048135A1 (en) | 2019-09-09 | 2021-03-18 | Basilea Pharmaceutica International AG | Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases |
WO2021062372A1 (en) | 2019-09-26 | 2021-04-01 | Amgen Inc. | Methods of producing antibody compositions |
JPWO2021060439A1 (pt) | 2019-09-26 | 2021-04-01 | ||
US20230242655A1 (en) * | 2019-12-03 | 2023-08-03 | Evotec International Gmbh | Interferon-associated antigen binding proteins and uses thereof |
JP2023509359A (ja) | 2019-12-17 | 2023-03-08 | フラグシップ パイオニアリング イノベーションズ ブイ,インコーポレーテッド | 鉄依存性細胞分解の誘導物質との併用抗癌療法 |
UY38995A (es) | 2019-12-20 | 2021-06-30 | Amgen Inc | Constructos de anticuerpo multiespecíficos agonistas de cd40 dirigidos a mesotelina para el tratamiento de tumores sólidos |
AR121013A1 (es) * | 2020-01-10 | 2022-04-06 | Symphogen As | Anticuerpos anti-cd40 y composiciones |
IL272194A (en) | 2020-01-22 | 2021-07-29 | Yeda Res & Dev | Multi-target antibodies for use in the treatment of diseases |
WO2021215462A1 (ja) | 2020-04-23 | 2021-10-28 | ブライトパス・バイオ株式会社 | 改良ペプチドワクチン |
AU2021271131A1 (en) | 2020-05-14 | 2022-12-15 | Molecular Partners Ag | Recombinant CD40 binding proteins and their use |
WO2021229067A1 (en) | 2020-05-14 | 2021-11-18 | Molecular Partners Ag | Multispecific proteins |
JP2023528017A (ja) | 2020-05-26 | 2023-07-03 | アンセルム(アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル) | 重症急性呼吸器症候群コロナウイルス2(sars-cov-2)ポリペプチドおよびワクチン目的でのその使用 |
GB202008003D0 (en) | 2020-05-28 | 2020-07-15 | Quine Medical Ab | Anti-CD40 antibody |
EP4162257A1 (en) | 2020-06-04 | 2023-04-12 | Amgen Inc. | Assessment of cleaning procedures of a biotherapeutic manufacturing process |
JP2023532339A (ja) | 2020-06-29 | 2023-07-27 | フラグシップ パイオニアリング イノベーションズ ブイ,インコーポレーテッド | サノトランスミッションを促進するためにエンジニアリングされたウイルス及び癌の処置におけるそれらの使用 |
EP4229080A1 (en) | 2020-10-15 | 2023-08-23 | Amgen Inc. | Relative unpaired glycans in antibody production methods |
EP4244253A1 (en) | 2020-11-12 | 2023-09-20 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Antibodies conjugated or fused to the receptor-binding domain of the sars-cov-2 spike protein and uses thereof for vaccine purposes |
MX2023007610A (es) | 2020-12-23 | 2023-07-12 | Inserm Institut National De La Sante Et De La Rech Medicale | Vacuna contra clamidia basada en el direccionamiento del antigeno momp vs4 a las celulas presentadoras de antigeno. |
TW202241479A (zh) | 2020-12-30 | 2022-11-01 | 美商安迅生物製藥公司 | 遞送外來抗原之溶瘤病毒及表現靶向外來抗原之嵌合受體之經工程化免疫細胞之組合療法 |
EP4277668A1 (en) | 2021-01-13 | 2023-11-22 | F. Hoffmann-La Roche AG | Combination therapy |
JP2024504195A (ja) | 2021-01-29 | 2024-01-30 | アンセルム(アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル) | クラミジア・トラコマチス抗原性ポリペプチドおよびワクチン目的のためのその使用 |
WO2022165260A1 (en) | 2021-01-29 | 2022-08-04 | Iovance Biotherapeutics, Inc. | Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy |
AU2022233547A1 (en) | 2021-03-09 | 2023-09-28 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in therapy |
JP2024512669A (ja) | 2021-03-31 | 2024-03-19 | フラグシップ パイオニアリング イノベーションズ ブイ,インコーポレーテッド | タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用 |
EP4352094A1 (en) | 2021-06-07 | 2024-04-17 | Amgen Inc. | Using fucosidase to control afucosylation level of glycosylated proteins |
CN117295764A (zh) * | 2021-06-28 | 2023-12-26 | 江苏恒瑞医药股份有限公司 | 抗cd40抗体、其抗原结合片段及医药用途 |
WO2023278641A1 (en) | 2021-06-29 | 2023-01-05 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
AU2022312698A1 (en) | 2021-07-13 | 2024-01-25 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
WO2023044048A1 (en) * | 2021-09-17 | 2023-03-23 | Novartis Ag | Methods for prevention of graft rejection in xenotransplantation |
CA3232917A1 (en) * | 2021-10-01 | 2023-04-06 | Mab Discovery Gmbh | Agonistic cd40 antibodies as immune stimulatory agents |
WO2023059607A1 (en) | 2021-10-05 | 2023-04-13 | Amgen Inc. | Fc-gamma receptor ii binding and glycan content |
WO2023088968A1 (en) | 2021-11-17 | 2023-05-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Universal sarbecovirus vaccines |
WO2023147488A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Cytokine associated tumor infiltrating lymphocytes compositions and methods |
WO2023172890A2 (en) * | 2022-03-07 | 2023-09-14 | Agenus Inc. | Anti-ilt2 antibodies and uses thereof |
WO2023193239A1 (en) | 2022-04-08 | 2023-10-12 | Peter Peizhi Luo | Anti-cd28 antibodies and methods of use thereof |
WO2023198851A1 (en) | 2022-04-14 | 2023-10-19 | Institut National de la Santé et de la Recherche Médicale | Methods for controlling the tumor cell killing by light |
WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
WO2024054992A1 (en) | 2022-09-09 | 2024-03-14 | Bristol-Myers Squibb Company | Methods of separating chelator |
WO2024059899A1 (en) * | 2022-09-20 | 2024-03-28 | Currus Biologics Pty Ltd | Bispecific polypeptides and uses thereof |
WO2024074571A1 (en) | 2022-10-05 | 2024-04-11 | Institut National de la Santé et de la Recherche Médicale | Dc-targeting vaccine against nipah virus infection |
WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
CN115969997B (zh) * | 2022-12-19 | 2024-02-13 | 华润生物医药有限公司 | 一种靶向cldn18.2的抗体药物偶联物及其应用 |
CN116375870B (zh) * | 2022-12-30 | 2023-09-15 | 优睿赛思(武汉)生物科技有限公司 | 抗人cd40蛋白的人源化抗体、制备方法及其应用 |
Family Cites Families (138)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US59427A (en) * | 1866-11-06 | Improvement in fences | ||
US439216A (en) * | 1890-10-28 | Maker | ||
US142358A (en) * | 1873-09-02 | Improvement in the purification of illuminating-gas | ||
US5179017A (en) * | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
US5168062A (en) * | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
WO1986005807A1 (en) | 1985-04-01 | 1986-10-09 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
US5750172A (en) * | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) * | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
US5175384A (en) * | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US5633076A (en) * | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
DE69120146T2 (de) * | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
US6150584A (en) * | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6713610B1 (en) * | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5151510A (en) * | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
WO1992003917A1 (en) * | 1990-08-29 | 1992-03-19 | Genpharm International | Homologous recombination in mammalian cells |
US5625126A (en) * | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) * | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5770429A (en) * | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5789650A (en) * | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
DE69233697T2 (de) | 1991-03-01 | 2008-01-24 | Dyax Corp., Cambridge | Verfahren zur Entwicklung von bindenden Mikroproteinen |
US5416367A (en) * | 1991-03-06 | 1995-05-16 | Quicklogic Corporation | Programmable application specific integrated circuit and logic cell therefor |
DE69233750D1 (de) | 1991-04-10 | 2009-01-02 | Scripps Research Inst | Bibliotheken heterodimerer Rezeptoren mittels Phagemiden |
ES2206447T3 (es) | 1991-06-14 | 2004-05-16 | Genentech, Inc. | Anticuerpo humanizado para heregulina. |
DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
AU2515992A (en) | 1991-08-20 | 1993-03-16 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
DK0605522T3 (da) | 1991-09-23 | 2000-01-17 | Medical Res Council | Fremgangsmåde til fremstilling af humaniserede antistoffer |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
JPH05242071A (ja) * | 1991-11-20 | 1993-09-21 | Mitsubishi Electric Corp | 対象システムを制御または決定・推定する方法、およびその装置 |
AU675929B2 (en) * | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
US5874082A (en) * | 1992-07-09 | 1999-02-23 | Chiron Corporation | Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation |
US5397703A (en) * | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
ATE381614T1 (de) | 1992-07-24 | 2008-01-15 | Amgen Fremont Inc | Bildung von xenogenen antikörpern |
US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
ES2146648T3 (es) * | 1993-03-09 | 2000-08-16 | Genzyme Corp | Procedimiento de aislamiento de proteinas de la leche. |
KR960704576A (ko) | 1993-10-01 | 1996-10-09 | 크리스토퍼 엘. 와이트 | CD40에 대한 항체(Antibodies to CD40) |
US5827690A (en) * | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
PT751781E (pt) * | 1993-12-23 | 2004-09-30 | Nat Inst Of Health As Repr By | Utilizacao de anticorpos monoclonais ou ligandos oligomericos soluveis no fabrico de um medicamento para a prevencao ou tratamento de desordens neoplasicas |
US5612126A (en) * | 1994-01-19 | 1997-03-18 | Burlington Industries, Inc. | Stiff fabric and method of forming the stiff fabric |
IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
JPH0812700A (ja) | 1994-07-01 | 1996-01-16 | Sumitomo Electric Ind Ltd | マウスcd40に対するモノクローナル抗体 |
US5643763A (en) * | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
GB9425060D0 (en) * | 1994-12-13 | 1995-02-08 | Univ Birmingham | Carcinoma treatment |
US6046037A (en) | 1994-12-30 | 2000-04-04 | Hiatt; Andrew C. | Method for producing immunoglobulins containing protection proteins in plants and their use |
US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
US6091001A (en) | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
US6132693A (en) * | 1995-04-11 | 2000-10-17 | Robert Bosch Gmbh | Process and device for reducing pollutants, especially nitrogen oxides in combustion exhaust gases |
CA2218503C (en) | 1995-04-20 | 2001-07-24 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives |
EP0826034A4 (en) | 1995-04-21 | 2002-06-19 | Cell Genesys Inc | PRODUCTION OF LARGE GENOMIC DNA DELETIONS |
ES2304786T3 (es) | 1995-04-27 | 2008-10-16 | Amgen Fremont Inc. | Anticuerpos anti-il-8 humanos, derivados a partir de xenoratones inmunizados. |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5880141A (en) * | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
US5780215A (en) * | 1995-07-26 | 1998-07-14 | Konica Corporation | Silver halide color photographic light-sensitive material |
GB9520822D0 (en) | 1995-10-11 | 1995-12-13 | Wellcome Found | Therapeutically active compounds |
US6440418B1 (en) * | 1995-11-07 | 2002-08-27 | Idec Pharmaceuticals Corporation | Methods of treating autoimmune diseases with gp39-specific antibodies |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
ATE225343T1 (de) | 1995-12-20 | 2002-10-15 | Hoffmann La Roche | Matrix-metalloprotease inhibitoren |
JP4464466B2 (ja) | 1996-03-05 | 2010-05-19 | アストラゼネカ・ユーケイ・リミテッド | 4―アニリノキナゾリン誘導体 |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
US5994619A (en) | 1996-04-01 | 1999-11-30 | University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus | Production of chimeric bovine or porcine animals using cultured inner cell mass cells |
EP0818442A3 (en) | 1996-07-12 | 1998-12-30 | Pfizer Inc. | Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor |
TR199900048T2 (xx) | 1996-07-13 | 1999-04-21 | Glaxo Group Limited | Protein tirozin kinaz inhibit�rleri olarak bisiklik heteroaromatik bile�ikler |
HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
ES2186908T3 (es) | 1996-07-13 | 2003-05-16 | Glaxo Group Ltd | Compuestos heterociciclos condensados como inhibidores de pproteina-tirosina-quinasas. |
HUP9903014A3 (en) | 1996-07-18 | 2000-08-28 | Pfizer | Phosphinate derivatives having matrix metalloprotease inhibitor effect and medicaments containing the same |
US6153609A (en) | 1996-08-23 | 2000-11-28 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
US5817690A (en) * | 1996-08-27 | 1998-10-06 | American Home Products Corporation | 4-aminoethoxy indolone derivatives |
ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
DK1500329T3 (da) | 1996-12-03 | 2012-07-09 | Amgen Fremont Inc | Humane antistoffer, der specifikt binder TNF-alfa |
CA2277100C (en) | 1997-01-06 | 2005-11-22 | Pfizer Inc. | Cyclic sulfone derivatives |
TR199901849T2 (xx) | 1997-02-03 | 2000-02-21 | Pfizer Products Inc. | Arils�lfonilamino hidroksamik asit t�revleri. |
CA2279863A1 (en) | 1997-02-07 | 1998-08-13 | Pfizer Inc. | N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases |
NZ336836A (en) | 1997-02-11 | 2001-02-23 | Pfizer | Arylsulfonyl hydroxamic acid derivatives suitable for a broad range of medicinal treatments |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
CA2289102A1 (en) | 1997-05-07 | 1998-11-12 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
EP1724282B1 (en) | 1997-05-21 | 2013-05-15 | Merck Patent GmbH | Method for the production of non-immunogenic proteins |
JP2002501532A (ja) | 1997-05-30 | 2002-01-15 | メルク エンド カンパニー インコーポレーテッド | 新規血管形成阻害薬 |
ATE368665T1 (de) | 1997-08-22 | 2007-08-15 | Astrazeneca Ab | Oxindolylchinazolinderivate als angiogenesehemmer |
EP1017682A4 (en) | 1997-09-26 | 2000-11-08 | Merck & Co Inc | NEW ANGIOGENESIS INHIBITORS |
CN1280580A (zh) | 1997-11-11 | 2001-01-17 | 辉瑞产品公司 | 用作抗癌药的噻吩并嘧啶和噻吩并吡啶衍生物 |
GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
US6051228A (en) | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
JP2002505097A (ja) | 1998-03-03 | 2002-02-19 | アブジェニックス インク. | 治療薬としてのcd147結合分子 |
JP4462654B2 (ja) | 1998-03-26 | 2010-05-12 | ソニー株式会社 | 映像素材選択装置及び映像素材選択方法 |
PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
AU4009899A (en) * | 1998-05-23 | 1999-12-13 | Tanox, Inc. | Molecules targeting cd40 and tumor cells |
HUP0103617A2 (hu) | 1998-05-29 | 2002-02-28 | Sugen, Inc. | Protein kinázt gátló, pirrolilcsoporttal helyettesített 2-indolszármazékok, e vegyületeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása |
EP1105427A2 (en) | 1998-08-17 | 2001-06-13 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
DK1004578T3 (da) | 1998-11-05 | 2004-06-28 | Pfizer Prod Inc | 5-oxo-pyrrolidin-2-carboxylsyrehydroxamidderivater |
AU776910B2 (en) | 1998-12-08 | 2004-09-23 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Modifying protein immunogenicity |
KR100856446B1 (ko) | 1998-12-23 | 2008-09-04 | 화이자 인크. | Ctla-4에 대한 인간 단일클론 항체 |
WO2000066155A1 (en) * | 1999-04-30 | 2000-11-09 | La Jolla Institute For Allergy And Immunology | Methods for preventing reactivation of latent virus and controlling virus replication |
US20030118588A1 (en) * | 1999-05-22 | 2003-06-26 | Linda Diehl | Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40 |
US6946129B1 (en) * | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
US6482411B1 (en) * | 1999-08-27 | 2002-11-19 | Board Of Regents, The University Of Texas System | Methods of reducing bone loss with CD40 ligand |
US6517529B1 (en) | 1999-11-24 | 2003-02-11 | Radius International Limited Partnership | Hemodialysis catheter |
GB9927757D0 (en) * | 1999-11-25 | 2000-01-26 | Kennedy Rheumatology Inst | Treatment of autoimmune diseases |
WO2001056603A1 (en) * | 2000-02-01 | 2001-08-09 | Tanox, Inc. | Cd40-binding apc-activating molecules |
AU2001259215A1 (en) * | 2000-04-28 | 2001-11-12 | La Jolla Institute For Allergy And Immunology | Human anti-cd40 antibodies and methods of making and using same |
US7063845B2 (en) | 2000-04-28 | 2006-06-20 | Gemini Science, Inc. | Human anti-CD40 antibodies |
US20030059427A1 (en) | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
AR032028A1 (es) | 2001-01-05 | 2003-10-22 | Pfizer | Anticuerpos contra el receptor del factor de crecimiento similar a insulina |
AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
SV2006001990A (es) | 2004-01-09 | 2006-01-30 | Pfizer | Anticuerpos contra madcam |
US9672526B2 (en) | 2012-03-13 | 2017-06-06 | American Express Travel Related Services Company, Inc. | Systems and methods for tailoring marketing |
US10884952B2 (en) | 2016-09-30 | 2021-01-05 | Intel Corporation | Enforcing memory operand types using protection keys |
-
2002
- 2002-11-05 AR ARP020104222A patent/AR039067A1/es active IP Right Grant
- 2002-11-06 HN HN2002000318A patent/HN2002000318A/es unknown
- 2002-11-08 KR KR1020047006992A patent/KR100830086B1/ko active IP Right Grant
- 2002-11-08 CN CN201310141396.7A patent/CN103450360B/zh not_active Expired - Lifetime
- 2002-11-08 GE GE5640A patent/GEP20074222B/en unknown
- 2002-11-08 US US10/292,088 patent/US7288251B2/en active Active
- 2002-11-08 AU AU2002356926A patent/AU2002356926B2/en not_active Expired
- 2002-11-08 WO PCT/US2002/036107 patent/WO2003040170A2/en active Application Filing
- 2002-11-08 RS YU39204A patent/RS52484B/en unknown
- 2002-11-08 GT GT200200228A patent/GT200200228A/es unknown
- 2002-11-08 IL IL16182302A patent/IL161823A0/xx unknown
- 2002-11-08 DK DK02802898.3T patent/DK1476185T3/da active
- 2002-11-08 MX MXPA04004467A patent/MXPA04004467A/es active IP Right Grant
- 2002-11-08 ME MEP-2008-814A patent/ME00503B/me unknown
- 2002-11-08 ES ES02802898T patent/ES2432968T3/es not_active Expired - Lifetime
- 2002-11-08 AP APAP/P/2004/003034A patent/AP1918A/en active
- 2002-11-08 OA OA1200400136A patent/OA12725A/en unknown
- 2002-11-08 PL PL392809A patent/PL214634B1/pl unknown
- 2002-11-08 PT PT28028983T patent/PT1476185E/pt unknown
- 2002-11-08 EP EP02802898.3A patent/EP1476185B1/en not_active Expired - Lifetime
- 2002-11-08 CA CA2466128A patent/CA2466128C/en not_active Expired - Lifetime
- 2002-11-08 JP JP2003542215A patent/JP4616555B2/ja not_active Expired - Fee Related
- 2002-11-08 BR BRPI0214137A patent/BRPI0214137B8/pt not_active IP Right Cessation
- 2002-11-08 CN CN028245709A patent/CN1582165B/zh not_active Expired - Lifetime
- 2002-11-08 EP EP10011765A patent/EP2343086A3/en not_active Withdrawn
- 2002-11-08 PL PL370514A patent/PL214289B1/pl unknown
- 2002-11-08 EA EA200400654A patent/EA011449B1/ru unknown
- 2002-11-08 HU HU0402247A patent/HU229829B1/hu unknown
- 2002-11-08 SI SI200231036T patent/SI1476185T1/sl unknown
- 2002-11-08 NZ NZ533180A patent/NZ533180A/en not_active IP Right Cessation
- 2002-11-08 MY MYPI20024189A patent/MY137641A/en unknown
- 2002-11-09 EG EG2002111224A patent/EG25801A/xx active
- 2002-11-11 NI NI200200128A patent/NI200200128A/es unknown
- 2002-11-11 DO DO2002000507A patent/DOP2002000507A/es unknown
- 2002-11-11 PE PE2002001093A patent/PE20030846A1/es active IP Right Grant
- 2002-11-11 TW TW091133017A patent/TWI331040B/zh not_active IP Right Cessation
- 2002-11-11 UY UY27537A patent/UY27537A1/es not_active Application Discontinuation
- 2002-11-11 TW TW099114882A patent/TWI338579B/zh not_active IP Right Cessation
- 2002-11-12 PA PA20028557701A patent/PA8557701A1/es unknown
-
2004
- 2004-04-05 MA MA27607A patent/MA27139A1/fr unknown
- 2004-05-04 EC EC2004005093A patent/ECSP045093A/es unknown
- 2004-05-05 TN TNP2004000078A patent/TNSN04078A1/fr unknown
- 2004-05-06 IS IS7253A patent/IS2940B/is unknown
- 2004-05-06 IL IL161823A patent/IL161823A/en active IP Right Grant
- 2004-05-10 CU CU20040097A patent/CU23745A3/es active IP Right Grant
- 2004-05-13 CR CR7343A patent/CR7343A/es unknown
- 2004-05-28 ZA ZA2004/04207A patent/ZA200404207B/en unknown
- 2004-06-08 NO NO20042388A patent/NO334339B1/no not_active IP Right Cessation
- 2004-06-08 HR HRP20040525AA patent/HRP20040525B1/hr not_active IP Right Cessation
-
2005
- 2005-03-22 HK HK05102440.7A patent/HK1069122A1/xx not_active IP Right Cessation
- 2005-08-25 US US11/211,917 patent/US7338660B2/en not_active Expired - Lifetime
- 2005-08-26 US US11/213,575 patent/US7563442B2/en active Active
-
2007
- 2007-09-25 US US11/904,295 patent/US7618633B2/en not_active Expired - Lifetime
-
2008
- 2008-09-22 US US12/284,605 patent/US7626012B2/en not_active Expired - Lifetime
-
2009
- 2009-06-19 CR CR10878A patent/CR10878A/es unknown
- 2009-08-27 CL CL2009001779A patent/CL2009001779A1/es unknown
- 2009-10-09 US US12/576,459 patent/US20100098694A1/en not_active Abandoned
-
2010
- 2010-03-31 JP JP2010081224A patent/JP5547532B2/ja not_active Expired - Fee Related
-
2012
- 2012-05-14 US US13/471,395 patent/US8388971B2/en not_active Expired - Lifetime
- 2012-09-14 US US13/619,954 patent/US20130024956A1/en not_active Abandoned
- 2012-12-12 JP JP2012270885A patent/JP5848232B2/ja not_active Expired - Lifetime
-
2013
- 2013-10-16 CY CY20131100904T patent/CY1115675T1/el unknown
-
2015
- 2015-08-06 US US14/820,040 patent/US20160152713A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0214137A (pt) | Anticorpos para o cd40, composição farmacêutica compreendendo os mesmos, uso dos mesmos na fabricação de um medicamento, linhagem, de célula isolada, molécula de ácido nucléico isolada, vetor compreendendo a mesma, célula hospedeira e método de fabricação dos referidos anticorpos | |
BRPI0413272A (pt) | anticorpos para c-met | |
BRPI0414269A (pt) | anticorpos para m-csf | |
CY1109423T1 (el) | Ανθρωπινα μονοκλωνα αντισωματα αντι-ιντελευκινης-5 και μεθοδοι και συνθεσεις που τα περιεχουν | |
BR112022014667A2 (pt) | Anticorpos de domínio único de cd28 e construtos multivalentes e multiespecíficos dos mesmos | |
BR0116728A (pt) | Anticorpos para receptor de fator de crescimento i semelhante à insulina | |
EP3530736A3 (en) | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics | |
BR0317358A (pt) | Composto de pirrolopiridazina, processo para sua preparação, composição farmacêutica contendo o mesmo, método de prevenção ou tratamento de doenças contendo o mesmo e seu uso | |
WO2020076977A3 (en) | Dll3 single domain antibodies and therapeutic compositions thereof | |
BRPI0411510A (pt) | proteìna, composição farmacêutica, uso da proteìna, polipeptìdeo, uso do mesmo, vetor, ácido nucleico, célula hospedeira, soro policlonal, anticorpo monoclonal, uso de um soro policlonal ou de um anticorpo monoclonal, método para alvejar in vitro uma molécula de interesse com as células que expressam cd11b, células que expressam cd11b, produto de terapia celular para imunizar um ser humano ou um animal contra um antìgeno uso de células que expressam cd11b, e, método para imunizar um paciente contra antìgeno | |
UA84539C2 (ru) | Человеческое моноклональное антитело, которое специфически связывается с cd40, фармацевтическая композиция, которая его содержит, и применение антитела для производства лекарственного средства для лечения cd 40-отрицательной опухоли у человека | |
TH42174A3 (th) | แอนติบอดีที่ทำให้เหมือนมนุษย์ซึ่งจำเพาะสำหรับ 4-1bb ของมนุษย์และสารผสมทางเภสัชกรรม ซึ่งประกอบด้วยสิ่งเดียวกัน |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B15G | Petition not considered as such [chapter 15.7 patent gazette] |
Free format text: DESCONHECIDA A TRANSFERENCIA SOLICITADA NA PETICAO NO 020090061887/RJ DE 24/06/2009, UMA VEZ QUE O DEPOSITO DE PATENTE JA SE ENCONTRA NO NOME DO CESSIONARIO. |
|
B25D | Requested change of name of applicant approved |
Owner name: PFIZER PRODUCTS INC. (US) , AMGEN FREMONT INC. (US Free format text: ALTERADO DE: ABGENIX, INC. |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B25B | Requested transfer of rights rejected |
Owner name: PFIZER PRODUCTS INC. (US) , AMGEN FREMONT INC. (US |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/03/2019, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/11/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B21A | Patent or certificate of addition expired [chapter 21.1 patent gazette] |
Free format text: PATENTE EXTINTA EM 08/11/2022 |